Microbial CRDMO Solutions with excellence in quality and global regulatory compliance
Vaccine
Vaccines stimulate protective immunity through controlled exposure to antigens or whole pathogens. Traditional types include subunit, conjugate, toxoid, inactivated, and live-attenuated vaccines, while new technologies such as mRNA, DNA, and VLP vaccines are reshaping vaccine development.
Yaohai Bio-Pharma offers end-to-end microbial CRDMO services for vaccine projects, including DNA vaccines, mRNA vaccines, VLP vaccines, and more — enabling smooth transition from R&D to commercialization.
Yaohai Bio-Pharma offers end-to-end CRDMO services for vaccine development, including microbial cell banking, process development, analytical method development, GMP manufacturing, quality control, and regulatory filing support — enabling efficient transition from early-stage development to commercial production.
Yaohai Bio-Pharma delivers tailored solutions for global clients, meeting diverse project requirements with excellence and efficiency.
Proven Project Excellence
Proven track record of over 100 successful projects, spanning preclinical studies and Phase I/II/III clinical trials, including US–China dual submissions and Australian regulatory filings.
Regulatory Compliance Assurance
A robust GMP-aligned quality system with standardized SOPs, fully compliant with global regulatory guidelines across the entire product lifecycle.
Expert Team Support
Powered by industry-leading scientists and cross-functional experts, our team delivers CRDMO projects with speed, precision, and deep technical insight.
